You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. UROGEN PHARMA LTD

UroGen Pharma Ltd XNAS: URGN

UroGen Pharma Ltd Live Share Price Today, Share Analysis and Chart

Download real time

9.88 0.21 (2.17%)

52.27% Fall from 52W High

105.7K XNAS Volume

XNAS 21 Apr, 2025 11:12 AM (EDT)

Watchlist

Portfolio

Share

UroGen Pharma Ltd Key Metrics

Default

Market Capitalization

Below industry Median
455.4

PE TTM

Negative PE TTM
-3.6

PEG TTM

High in industry
0.1

Price to Book

Negative Price to Book
-51.7

Institutional holding current Qtr %

Below industry Median
14.9

Revenue Growth Qtr YoY %

Below industry Median
4.4

Operating Revenue growth TTM %

Below industry Median
9.3

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-44.2

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-24.1

Operating Profit Margin Qtr %

Negative Operating Profit Margin Qtr %
-112.6

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-107.1

Piotroski Score

Low in industry
1

Rel Perf vs Sector quarter%

-3.7

RoA Annual %

Negative RoA Annual %
-54.7
All financials are in USD Million and price data in USD
VIEW MORE

10

S

10

W

3

O

2

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


UroGen Pharma Ltd Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '260200400Actual RevenueAvg. Estimate
Miss

UroGen Pharma Ltd's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

Current EPS
-3
Avg. Estimate
-2.8
Low Estimate
-3.3
High Estimate
-1.7
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 6.4% in FY25

Consensus Recommendation

7 ANALYST Recommendations
STRONG BUY

Created with Highcharts 7.2.21Hold1Buy5Strong Buy

The consensus recommendation from 7 analysts for UroGen Pharma Ltd is STRONG BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

UroGen Pharma Ltd Stock Analysis

UroGen Pharma Ltd stock analysis with key metrics, changes, and trends.

UroGen Pharma Ltd MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$90.4 M9.29%positive

Annual Revenue rose 9.29%, in the last year to $90.4 M. Its sector's average revenue growth for the last fiscal year was 7.54%.

Annual Net Profit$126.87 M24.09%negative

Annual Net Profit fell 24.09% in the last year to $126.87 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

Price to Earning Ratio-3.59-negative

Price to Earning Ratio is -3.59, which is negative.

Stock Price$9.88-28.04%negative

Stock Price fell 28.04% and underperformed its sector by 35.4% in the past year.

Quarterly Revenue$24.56 M4.4%positive

Quarterly Revenue rose 4.4% YoY to $24.56 M. Its sector's average revenue growth YoY for the quarter was 5.84%.

Quarterly Net profit$37.51 M44.19%negative

Quarterly Net profit fell 44.19% YoY to $37.51 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

Mutual Fund Holding15.23 %-0.5%negative

Mutual Fund Holding decreased by 0.5% in the last quarter to 15.23.

Promoter Share Holding4.33 %0.05%positive

Promoter Share Holding increased by 0.05% in the most recent quarter to 4.33%.

Interest Coverage Ratio-8.91-negative

Interest Coverage Ratio is -8.91, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding14.87 %0.13%positive

Institutional Holding increased by 0.13% in the last quarter to 14.87.

VIEW LESS


Loading data..

UroGen Pharma Ltd - Company Profile

What does UroGen Pharma Ltd do?

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

UroGen Pharma Ltd Management structure

All Gross Remunerations are in USD
Mr. Christopher Degnan
Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Mr. Dong Kim
Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Ms. Elizabeth Barrett
Director, President and Chief Executive Officer
-
2024
Gross Remuneration
Year

UroGen Pharma Ltd Board of directors

All Gross Remunerations are in USD
Dr. Fred E. Cohen, D.Phil.,F.A.C.P.,M.D.
Independent Director
-
2024
Gross Remuneration
Year
Dr. Arie S. Belldegrun, F.A.C.S.,M.D.
Chairman of the Board
-
2024
Gross Remuneration
Year
Ms. Cynthia M. Butitta
Independent Director
-
2024
Gross Remuneration
Year
Dr. Stuart Holden, M.D.
Independent Director
-
2024
Gross Remuneration
Year
Mr. James A. Robinson, Jr
Independent Director
-
2024
Gross Remuneration
Year
Ms. Elizabeth Barrett
Director, President and Chief Executive Officer
-
2024
Gross Remuneration
Year

UroGen Pharma Ltd FAQ

How is UroGen Pharma Ltd today?
UroGen Pharma Ltd today is trading in the green, and is up by 2.17% at 9.88.
UroGen Pharma Ltd is currently trading up 2.17% on an intraday basis. In the past week the stock fell -2.37%. stock has been down -3.80% in the past quarter and fell -28.04% in the past year. You can view this in the overview section.